- Home
- IRON vs BUSE Comparison
IRON vs BUSE Comparison
Compare IRON & BUSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- BUSE
- Stock Information
- Founded
- IRON 2017
- BUSE 1868
- Country
- IRON United States
- BUSE United States
- Employees
- IRON N/A
- BUSE N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- BUSE Major Banks
- Sector
- IRON Health Care
- BUSE Finance
- Exchange
- IRON Nasdaq
- BUSE Nasdaq
- Market Cap
- IRON 2.0B
- BUSE 2.0B
- IPO Year
- IRON N/A
- BUSE N/A
- Fundamental
- Price
- IRON $60.35
- BUSE $24.17
- Analyst Decision
- IRON Strong Buy
- BUSE Buy
- Analyst Count
- IRON 11
- BUSE 7
- Target Price
- IRON $95.73
- BUSE $27.29
- AVG Volume (30 Days)
- IRON 325.5K
- BUSE 464.4K
- Earning Date
- IRON 08-07-2025
- BUSE 07-22-2025
- Dividend Yield
- IRON N/A
- BUSE 4.31%
- EPS Growth
- IRON N/A
- BUSE N/A
- EPS
- IRON N/A
- BUSE 1.13
- Revenue
- IRON N/A
- BUSE $498,525,000.00
- Revenue This Year
- IRON N/A
- BUSE $62.96
- Revenue Next Year
- IRON N/A
- BUSE $11.57
- P/E Ratio
- IRON N/A
- BUSE $20.57
- Revenue Growth
- IRON N/A
- BUSE 16.77
- 52 Week Low
- IRON $30.82
- BUSE $18.40
- 52 Week High
- IRON $68.73
- BUSE $28.30
- Technical
- Relative Strength Index (RSI)
- IRON 57.22
- BUSE 64.66
- Support Level
- IRON $57.54
- BUSE $23.01
- Resistance Level
- IRON $64.83
- BUSE $23.56
- Average True Range (ATR)
- IRON 2.14
- BUSE 0.45
- MACD
- IRON -0.19
- BUSE 0.13
- Stochastic Oscillator
- IRON 46.60
- BUSE 97.68
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About BUSE First Busey Corporation
First Busey Corporation is a financial holding company, whose subsidiaries provides retail and commercial banking services, remittance processing, and offers financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech and Wealth Management. The banking segment generates a vast majority of its revenue.